Importantly, EZH2 is essential for tumor formation after conditional loss of SMARCB1 in mice (Wilson et al. 2010), and treatment with small molecule EZH2 inhibitors led to regression of RT in a xenograft model (Knutson et al. 2013). The gene discussed is SMARCB1; the disease is neoplasm.